Latest Conference Articles

Nicholas A. Butowski, MD, discusses an early-stage study of convection-enhanced delivery of nanoliposomal irinotecan with real-time imaging.

Maciej M. Mrugala, MD, PhD, discusses a retrospective analysis looking at adding cycles of treatment with temozolomide in newly diagnosed patients with glioblastoma.

Amy B. Heimberger, MD, discusses the potential of FGL2 as a multi-modality regulator of tumor-mediated immune suppression in patients with glioblastoma.

Georgina Long, BSc, PhD, MBBS, FRACP, medical oncologist, translational researcher, Melanoma Institute Australia, The University of Sydney, discusses which patients may benefit from the combination of dabrafenib and trametinib based on several recent clinical trials.

Victoria Atkinson, MD, of Princess Alexandra Hospital and Gallipoli Medical Research Foundation, Queensland, discusses long-term data from the phase III CheckMate-066 trial.

John H. Sampson, MD, PhD, MBA, MHSc, discusses results from cohort 1 of the CHECKMATE-143 trial.

David Reardon, MD, discusses updated survival findings from the phase II ReACT trial, which analyzed rindopepimut (CDX-110) plus bevacizumab for the treatment of relapsed glioblastoma.

Jason Luke, MD, Assistant Professor of Medicine, the University of Chicago Medicine Comprehensive Cancer Center, discusses how inflammation in the tumor microenvironment can serve as a biomarker in melanoma.

Michael Krauthammer, MD, PhD, Associate Professor of Pathology, Yale School of Medicine, discusses the role of NF1 mutation in melanoma.

Sancy Leachman, MD,PhD, Professor and Chair, Department of Dermatology Director, Melanoma Research Program, Knight Cancer Institute, Oregon Health & Science University, discusses a new tool that oncologists can use with patients to identify melanoma recurrences.

Sheri Holmen, PhD, investigator, Associate Professor in the Department of Surgery, Adjunct Professor in the Department of Oncological Sciences, Huntsman Cancer Institute, the University of Utah School of Medicine, discusses understanding drivers for melanoma metastasis.

Marcia Brose, MD, PhD, associate professor of Otorhinolaryngology, Head and Neck Surgery, at the Hospital of the University of Pennsylvania, discusses the lenvatinib trial.

Thomas J. Lynch, MD, CEO, chairman, Massachusetts General Hospital Physicians Organization, discusses targeting EGFR mutation subtypes as a frontline treatment for lung cancer.

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses advancements in polycythemia vera (PV).

Samuel Waxman, MD, Distinguished Service Professor of Medicine, Hematology and Medical Oncology, Distinguished Service Professor of Oncological Sciences, Mount Sinai Health System, discusses advancements in treating patients with acute promyelocytic leukemia.

Alec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association (LUGPA), discusses targeted focal therapy for localized prostate cancer.

Gary Kirsh, MD, president of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses the future of treatment for prostate cancer.

John Marshall, MD, Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses the importance of molecular testing in colorectal cancer.

Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses how to define resistance to EGFR-inhibitors in lung cancer.

Benjamin P. Levy, MD, attending physician, Department of Medicine, Mount Sinai Beth Israel and Mount Sinai St. Luke's Roosevelt, Mount Sinai Health System, discusses EGFR TKIs for the treatment of patients with lung cancer.

Philip J. Buffington, MD, chief medical officer at The Urology Group, discusses administering degarelix (Firmagon) and determining which patients to treat with the hormonal therapy.buffington-thumb.jpg

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses results seen with anti–PD-1/PD-L1 treatments in lung cancer.

Dr. Renato G. Martins talks about the impact of nivolumab, an anti–PD-1, and ipilimumab, an anti CTLA-4, in the treatment of lung cancer.

Deepak A. Kapoor, MD, chairman and CEO of Integrated Medical Professionals and Large Urology Group Practice Association's (LUGPA's) chairman of health policy, discusses LUGPA's legislative advocacy efforts.

Raoul S. Concepcion, MD, FACS, director of Advanced Therapeutics at Urology Associates, PC, discusses healthcare's movement away from fee-for-service reimbursements.

Jeffrey S. Weber, MD, PhD, deputy director, Laura and Isaac Perlmutter Cancer Center, co-director of its Melanoma Program and Head of Experimental Therapeutics, NYU Langone Medical Center, discusses the significance of the FDA approval of the combination of dabrafenib and trametinib for patients with unresectable or metastatic melanoma who harbor a BRAF V600E or V600K mutation.

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses emerging therapies for patients with triple-negative breast cancer.

Tony Philip, MD, medical oncologist, Monter Cancer Center of the North Shore-LIJ Cancer Institute, assistant professor of Medicine, Hofstra-North Shore LIJ School of Medicine and NYIT College of Osteopathic Medicine, discusses approved and emerging agents for soft tissue sarcomas.

Evan R. Goldfischer, MD, MBA, FACS, director of the Research Department at Premier Medical Group of the Hudson Valley, discusses the benefits of integrated medical groups.

Patrick I. Borgen, MD, chair, Department of Surgery, head, Brooklyn Cancer Center, Maimonides Medical Center, compares the efficacy of surgical versus medical treatment of patients with breast cancer.